NCT04740242

Metabolic Alkalosis in Heart Failure

ALCALOTIC Study: Metabolic Alcalosis in Decompensated Heart Failure: Prevalence and Influence on Prognosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 672 (actual)
• Sponsor: Spanish Society of Internal Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Metabolic alkalosis (MA) is the most common acid-base disorder and when it's severe it can have effects on cellular function and contribute to an increase in mortality. MA is a common complication of heart failure (HF) especially when patients are treated with diuretics, but few studies have analyzed the prevalence of acid-base disorders in patients with HF. All these studies have shown that MA is more common in patients with HF in more advanced stages and that the use of diuretics increases the prevalence of MA. The study hypothesis, based on clinical experience and the few data that exist in the scientific literature, is that MA is a frequent analytical disorder in patients admitted for decompensated HF and that its presence entails a worse short-term vital prognosis. The ALCALOTIC study is an observational cohort and prospective study. The main objectives of the study are the following: 1. To determine the prevalence of MA in patients admitted for decompensated HF 2. To analyze if there are differences in patients admitted for HF according to the presence of MA on admission 3. To determine if the presence of MA has an influence on the short-term prognosis in patients admitted for decompensated HF

Conditions

• Heart Failure
• Metabolic Alkalosis
• Diuretics Drug Reactions
• Decompensated Heart Failure
• Acute Heart Failure

Timeline

• Start date: 2021-01-01
• Primary completion: 2021-05-31
• Completion: 2021-09-30
• First posted: 2021-02-05
• Last updated: 2022-05-04

Locations

1 site across 1 country: Spain